More on Aeterna Zentaris (AEZS): Q4 beats consensus estimates on both its EPS loss as well...

|By:, SA News Editor

More on Aeterna Zentaris (AEZS): Q4 beats consensus estimates on both its EPS loss as well revenue. Total sales declined 24% Y/Y, mainly due to the recording of a $2.6M milestone payment from Yakult for the initiation of Phase 1 trials for perifosine in Japan during Q411. Operational expenses declined due to lower employee compensation and benefit costs and a reduced headcount at the drug developer.